Tag:
leukemia
Latest Headlines
Latest Headlines
Receptor picks out aggressive leukemia
In a presentation at FASEB 2012, a team of researchers from the University of California talked about a possible marker on the surface of the cells.
FDA to rule soon on Tekmira-created nanoparticle chemo drug
May 13 is the do-or-die date for Marqibo, a nanoparticle-delivered injectable cancer drug conceived by Canada's Tekmira Pharamceuticals ( $TKMR ).
Biomarkers expose child cancer treatment heart risk
Doxorubicin is used to treat acute lymphoblastic leukemia (ALL) in children. ALL is a cancer of the blood that can kill within a few weeks if left untreated. But this drug that can save lives also...
Novartis cancer drugs stymie deadly Ebola virus
A pair of Novartis ( $NVS ) leukemia drugs effectively attacked the highly lethal Ebola virus in lab tests, providing clues about what it might take to finally march forward with a treatment against the killer bug.
Can omega-3 fatty acids beat back cancer? Maybe not
Let the fight continue to rage over whether drugs and supplements made from omega-3 fatty acids have any therapeutic effect. We’ve told you about recent research that suggests that fish oil and...
EntreMed lands $10M deal to fund cancer drug trials
EntreMed ( $ENMD ) has struck a deal to bring in much-needed capital to support development of its experimental kinase inhibitor for attacking multiple types of cancer. And the Rockville, MD-based drug
Fish oil wipes out leukemia in mice
Fish oil may have yet another use--as a weapon to wipe out leukemia cells. Penn State scientists have discovered that a compound derived from fish oil targets and kills leukemia stem cells in the
Leukemia sequencing picks out potential DNA biomarkers
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia. It usually is slow to develop and many people don't need treatment for months or even years; however, others will need
Pharmacyclics impresses (again) with improved leukemia data on blockbuster hopeful
Anyone looking for a solid reason why J&J's Janssen would pay $150 million upfront to partner on Pharmacyclics' experimental blood cancer drug need look no further than the leukemia data the
Ariad's ponatinib takes center stage with promising pivotal leukemia data
Ariad Pharmaceuticals ( $ARIA ) took center stage at the big American Society of Hematology (ASH) meeting over the weekend with interim pivotal data demonstrating that close to half of all chronic
